Laser treatment to reduce eye drops in glaucoma and high eye pressure
Tests a laser treatment to cut medication use in glaucoma or ocular hypertension.
Plain-language title generated from the registry record
Registry title: DSLT for Reducing Medication in Glaucoma
Key facts
- Where
- Largo, United StatesSee the site
Where in United States
- The Eye Institute of West FloridaLargo, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The Eye Institute of West Florida
- Trial code
- NCT07390890
- Record updated
- 20 April 2026
- Original description
This is a prospective, single arm, open label study conducted at a single site to evaluate the efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in reducing medication burden in patients with medically controlled ocular hypertension or primary open angle glaucoma.Read full original descriptionShow less
Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) for Reducing Medication Burden in Medically Controlled Patients With Ocular Hypertension or Primary Open Angle Glaucoma
This is a prospective, single arm, open label study conducted at a single site to evaluate the efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in reducing medication burden in patients with medically controlled ocular hypertension or primary open angle glaucoma.
The study will assess the primary endpoint of reduction in medication count at 6 months compared to baseline. Secondary endpoints include IOP reduction compared to baseline (both percentage and absolute), complete success rate (no increase in IOP without medications), proportion of eyes needing medication at 6 months, and any secondary surgical interventions at 6 months post-DSLT.
Participants will undergo DSLT with 120 shots, 400 µm spot size, and 1.8mJ fixed energy delivered at the limbus over 2.4 seconds. Follow-up visits will occur at 1 month, 3 months, and 6 months post-procedure, with IOP measured using a calibrated Goldmann tonometer.
Inclusion: Adult patients scheduled to undergo DSLT treatment in one or both eyes; Diagnosis of ocular hypertension or primary open angle glaucoma (POAG); Medically controlled on 1-3 topical ocular hypotensive agents with IOP ≤21 mmHg.
Exclusion: Previous glaucoma surgeries/interventions:; Patients who have undergone prior glaucoma-related procedures (e.g., trabeculectomy, laser trabeculoplasty, MIGS, or tube shunt); Patients who have undergone cataract surgery within the prior 2 years; Secondary glaucoma:; Patients with secondary forms of glaucoma, such as angle-closure glaucoma, neovascular glaucoma, or glaucoma resulting from trauma or other systemic diseases; Other significant ocular conditions including advanced cataracts, retinal diseases (e.g., age-related macular degeneration), or any condition that might complicate the assessment of intraocular pressure (IOP) or visual function as deemed by the investigator.